Overcomes endosomal entrapment — a major obstacle to effective intracellular drug delivery
Enables local delivery of functional antisense oligonucleotides (ASOs) and other therapeutic cargos
Achieves rapid delivery into a wide range of cells and tissues, including the skin and lungs — two organs known for their challenging natural barriers that limit traditional delivery methods
With a robust safety profile demonstrated in preclinical studies, the Feldan Shuttle led to the advancement of our lead candidate, FLD-103, into clinical trials
Unlocking the Full Potential of Antisense Oligonucleotides with the Feldan Shuttle
Antisense oligonucleotides (ASOs) are a class of RNA therapeutics that selectively silence disease-driving genes. Despite their precision and therapeutic potential, ASOs face a major challenge: they cannot cross cell membranes on their own, limiting their effectiveness. The Feldan Shuttle addresses this barrier by efficiently delivering ASOs into cells, enabling them to reach their intracellular targets and achieve their intended therapeutic effect.
The Feldan Shuttle unlocks the therapeutic promise of ASOs and expands their application in novel therapies.
